Business Context and Reporting Period
Company: Altimmune, Inc.
Filing Type: Form 8-K (Current Report)
Date: March 21, 2023
Subject: Announcement of topline results from the Week 24 interim analysis of the MOMENTUM Phase 2 obesity trial and the 12-week Phase 1b safety trial for the investigational drug pemvidutide.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
MOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis)
- Study Design: 160 subjects completed 24 weeks of treatment; randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide, or placebo.
- Weight Loss Efficacy:
- 1.2 mg dose: 7.3% mean weight loss.
- 1.8 mg dose: 9.4% mean weight loss.
- 2.4 mg dose: 10.7% mean weight loss.
- Placebo: 1.0% mean weight loss.
- Responder Rates: Approximately 50% of subjects achieved ≥10% weight loss and 20% achieved ≥15% weight loss at the 1.8 mg and 2.4 mg doses.
- Subgroup Analysis: Subjects with baseline weight ≤115 kg achieved higher weight loss (up to 11.9% at 2.4 mg).
- Safety: Upper GI events (nausea, vomiting) were the majority of adverse events (AEs), predominantly mild to moderate. One serious AE (nausea/vomiting) occurred at the 2.4 mg dose. Discontinuation rates were 24.0% for pemvidutide vs. 28.2% for placebo.
Phase 1b Type 2 Diabetes Safety Trial (12-Week Results)
- Study Design: 54 subjects with type 2 diabetes randomized to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide, or placebo.
- Weight Loss Efficacy:
- 1.2 mg dose: 4.4% mean weight loss.
- 1.8 mg dose: 6.1% mean weight loss.
- 2.4 mg dose: 7.7% mean weight loss.
- Placebo: 0.8% mean weight gain.
- Safety: No serious adverse events (SAEs) observed. No AEs led to study discontinuation. Glucose homeostasis was maintained with no significant changes in fasting glucose or HbA1c.
Guidance, Outlook, and Risks
Management Commentary: The Company highlighted robust reductions in waist circumference and serum lipids, as well as clinically meaningful blood pressure reductions without significant heart rate increases. The safety profile was consistent with prior trials, with GI events being dose-related.
Outlook: The Company intends to host a conference call to discuss these results. The filing does not provide specific financial guidance or updated commercial timelines beyond the trial data.
Risks and Contingencies: The primary risks identified are gastrointestinal adverse events, which contributed to discontinuations in the obesity trial. The protocol did not allow for dose reduction due to intolerability, which may impact future trial designs or patient retention strategies.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and slide presentation (Exhibit 99.2) for detailed statistical analysis and methodology.
- Confirm the timeline for the completion of the full 48-week MOMENTUM trial and the planned Phase 3 development strategy.
- Review the Company's cash position and burn rate in the most recent 10-Q or 10-K to assess runway for continued clinical development.
- Monitor regulatory feedback regarding the safety profile, specifically the rate of GI-related discontinuations compared to competitor therapies.